Navigation Links
Oncolytics Biotech Inc. Announces 2008 First Quarter Results
Date:4/30/2008

om regressing tumors, levels of neutralizing antibodies that were protective, and only very mild toxicities. The data support investigation in human clinical trials of the use of cyclophosphamide prior to systemic reovirus administration to modulate, but not ablate, the immune system.

We also reported that Dr. Kevin Harrington and his research group at The Institute of Cancer Research, London, U.K. published the results of their work testing combination treatment schedules of reovirus and radiation in human and murine tumour cells in vitro and in vivo. The paper, entitled "Enhanced In vitro and In vivo Cytotoxicity of Combined Reovirus and Radiotherapy" appeared online in the February 1, 2008 issue of Clinical Cancer Research.

The effect of different schedules of reovirus and radiotherapy on viral replication and cytotoxicity was tested in vitro and the combination was assessed in three tumour models in vivo. The results demonstrated that combining reovirus and radiotherapy significantly increased cancer cell killing both in vitro and in vivo, particularly in cell lines with moderate susceptibility to reovirus alone.

As well, in the first quarter of 2008, we reported that Dr. Kevin Harrington and his research group at The Institute of Cancer Research, London, U.K. published the results of their work characterizing immune system responses to administration of intravenous REOLYSIN(R) in a Phase I clinical trial. The paper, entitled "Characterization of the Adaptive and Innate Immune Response to Intravenous Oncolytic Reovirus (Dearing Type 3) during a Phase I Clinical Trial" appeared online in the March 6, 2008 issue of Gene Therapy.

The investigators conducted a detailed analysis of the immune effects of intravenous viral therapy by collecting and analyzing immune response to the presence of the virus. The results suggest that reovirus may stimulate the immune system to mount a dynamic immune response to the presence of virus, increasing th
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... CHARLOTTESVILLE, Virginia , September 2, 2015 /PRNewswire/ ... Sponsoring der Gewinner des Wettbewerbs BeHEARD von 2015 ... einen internationalen vom Rare Genomics Institute. ... Wirksamkeit von Medikamenten für die Behandlung anderer Krankheiten ... wurde, Steven Laffoon und sein Team ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... members will be attending Pharma Ed Resources upcoming educational seminar and training ... industry leading speakers, this timely conference will provide Updates & Case Studies on ...
(Date:9/2/2015)... San Diego, CA (PRWEB) , ... September 02, ... ... from troubleshooting faults in manufacturing equipment, to creating professional commercial video content, to ... beautifully detailed views of fascinating events that go by too quickly to process ...
(Date:9/1/2015)... 2, 2015 Swecure, ... Forschung und Entwicklung neuartiger Therapien für Störungen ... und Reizdarm konzentriert, erhält vom US Patent ... neues Medikament patentiert wird. Das Medikament basiert ... Kindern verhindert und Entzündungen vorbeugt.   ...
Breaking Biology Technology:Biovista sponsert die Forschung von Wylder Nation Foundation zum Thema Mangel an saurer Sphingomyelinase 2Whitehouse Laboratories to Participate in Pharm Ed Resources Extractables, Leachables, & Elemental Impurities Educational Seminar 2Whitehouse Laboratories to Participate in Pharm Ed Resources Extractables, Leachables, & Elemental Impurities Educational Seminar 3Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 2Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 3Das Patent von Swecure zur Verhinderung von Allergien bei Kindern wird in den USA zugelassen 2
... Partners and Versant Ventures Lead ... Transform Clinical Microbiology, MADISON, Wis., Sept. 12 OpGen, ... equity financing. The round,was led by CHL Medical Partners, Highland ... participating. In,conjunction, CHL,s Ron Lennox will become chairman of the ...
... PHOENIX, Sept. 11 ThirdBiotech,( http://www.thirdbiotech.com ), ... has begun operations in Arizona. (Logo: ... of ThirdBiotech created the group to foster,networking ... and healthcare,community throughout the state. "It,s important ...
... LAKE CITY, Sept. 11 Dynatronics,Corporation (Nasdaq: ... quarter,and fiscal year ended June 30, 2007 during ... has scheduled a conference call for investors later ... results for the quarter and fiscal year.,Those interested ...
Cached Biology Technology:OpGen Announces $23.6 Million Series A Financing 2OpGen Announces $23.6 Million Series A Financing 3
(Date:8/12/2015)... Aug. 12, 2015   MedNet Solutions , an ... spectrum of clinical research, is proud to announce that ... comprehensive SaaS-based eClinical technology platform, has led the way ... two quarters of 2015.   Q2 2015 and Q1 ... measured by contract value sold in the company,s 15 ...
(Date:8/12/2015)... , Aug. 12, 2015  New research unveiled ... attack Android phones to steal users, fingerprints. Information ... availability of fingerprint scanners on mobile devices, making ... To secure biometrics on mobile devices, HYPR Corp. ... these convenient authentication systems with strong cryptographic security. ...
(Date:8/11/2015)... , August 11, 2015 Today, ZUK ... Already received as well as expected revenues in 2015 that relate ... FPC,s communicated revenue guidance of approximately 2,200 MSEK for 2015. ... is a prominent smartphone manufacturer in ... ZUK selected FPC1 155 for ...
Breaking Biology News(10 mins):MedNet Solutions Experiences Explosive Corporate Growth 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 3FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2
... in eastern U.S.,s forests before a blight wiped it out ... landscape thanks in part to work by a University of ... TIP). Once used extensively for building, for tanning ... wildlife, and even as nutritious fodder for hogs, the American ...
... (Santa Barbara, Calif.) New approaches are needed to ... environmental threats that lie ahead in the 21st century, ... The scientists propose that global biophysical boundaries, identified ... earth system, can define a "safe planetary operating space" ...
... the groundwater table has been dubbed the "Critical Zone" because ... and nutrients necessary for life. Now an interdisciplinary team ... Southwest with the help of a five-year, $4.35 million grant ... "We think of the critical zone as being a ...
Cached Biology News:Tennessee foresters helping to return chestnuts to American forests 2Scientists outline planetary boundaries: A safe operating space for humanity 2Scientists outline planetary boundaries: A safe operating space for humanity 3UA awarded $4.35 million to study Earth's critical zone 2UA awarded $4.35 million to study Earth's critical zone 3
{3,8-diamino-5-[3-(diethylmethylammonio)propyl]-6-phenylphenanthridinium diiodide}. ,250 ug/ml Propidium Iodide (PI) in PBS....
Detects activated caspases in living cells. Simple/sensitive/straight-forward procedure takes only 30 minutes. Results can be analyzed by flow cytometry/fluorescence microscopy/fluorescence plate rea...
Anti-Mouse Qa.m7, Ascites (Clone 5035-50.1) (mouse IgM)...
DAPI: 4', 6-Diamino-2-phenylindole dihydrochloride. Antifade Solution: p-Phenylenediamine and glycerol in PBS solution. 0.4g/mL DAPI suspended in Antifade....
Biology Products: